Stone JH, Wallace Z, Perugino CA, et al. Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease. ACR 2017, abstract 4L.
Hoe eerder, hoe beter? Debat over behandelen van artralgie
mrt 2020 | RA